Straits Times Index
3,434.23 +18.72 (+0.55%) Nikkei
40,928.52 +347.76 (+0.86%) Hang Seng
17,975.29 -3.28 (-0.02%) FTSE 100
8,171.12 +49.92 (+0.61%) Bitcoin USD
58,895.50 -2,058.73 (-3.38%) CMC Crypto 200
1,234.15 -100.77 (-7.55%)
Bristol-Myers Squibb Company (BMY.MX)
| Previous close | 745.00 |
| Open | 730.00 |
| Bid | 723.00 x 1400 |
| Ask | 735.00 x 3800 |
| Day's range | 725.00 - 730.00 |
| 52-week range | 676.60 - 1,093.85 |
| Volume | |
| Avg. volume | 4,746 |
| Market cap | 1.47T |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -56.99 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 44.52 (5.98%) |
| Ex-dividend date | 05 Jul 2024 |
| 1y target est | N/A |
ReutersBristol Myers to pay $2.7 million to settle Israel anti-competition charges
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday. The anti-trust agency said that Bristol and Neopharm Scientific, the Israeli distributor of Imnovid - used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma - declined a request by KS Kim International for drug samples to make a copycat version of Imnovid.
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
ZacksInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
